.png)
Roy Twyman, MD
Dr. Roy Twyman co-chairs a NINDS workshop on anti-epileptogenesis and epilepsy disease modification. He has extensive experience in developing therapeutics for epilepsy, migraine, multiple sclerosis, depression, and schizophrenia.
​
As senior VP at Janssen Pharmaceutical Research & Development LLC, he was the Alzheimer’s disease leader in the Neuroscience Therapeutic Area. There he focused on discovery, chemistry, biomarkers, translational medicine, early and late clinical development, diagnostics, and solutions involving patient care.
​
In 1998, Twyman joined the company previously known as the RW Johnson Pharmaceutical Research Institute. He had nine previous years in academia and was associate professor in the University of Utah’s department of neurology and department of pharmacology and toxicology.
​
He has served on advisory committees and panels of the U.S. Food and Drug Administration and the Institute of Medicine, and participated in a Special Committee on Epilepsy of the National Institute of Neurological Disorders and Stroke.
Dr. Twyman earned his medical degree and internship at the University of Kentucky before embarking on a neurology residency at the University of Michigan. There he served as chief resident and completed a fellowship in neuroelectrophysiology and epilepsy.
​
Board-certified in psychiatry and neurology, Twyman has written chapters in several books and published numerous articles in peer-reviewed, medical and scientific journals.
%20-%20Joe%20Horrigan.png)
Joseph Horrigan
Dr. Joe Horrigan is a pediatric neuropsychiatrist with over 30 years of clinical experience working with children and adults with neurodevelopmental disorders. He also 20 years of experience in the pharmaceutical and biotech industry, both as a clinical investigator and as a sponsor.
​
Dr. Horrigan began his industry career at GlaxoSmithKline (GSK). At GSK, he was Senior Director of Neurosciences Medicines Development Center, and co-founded and led the company-wide Medicines for Children Advisory Network. After GSK, he served as Assistant Vice President and Head of Medical Research for Autism Speaks, the largest science and advocacy foundation devoted to autism spectrum disorders (ASD) globally. Following Autism Speaks he served as Vice President of Clinical Development and Medical Affairs at Neuren Pharmaceuticals, where he led that company’s clinical development of trofinetide in Fragile X and Rett syndromes. After licensing to Acadia Pharma, trofinetide was subsequently approved in 2023 as the first treatment (DAYBUE™) for Rett syndrome. Chief Medical Officer at AMO Pharma (UK).
​
Dr. Horrigan received his Sc.B. degree from Brown University and his medical degree from the University of Rochester School of Medicine. Residency in Psychiatry at UNC Chapel Hill School of Medicine where he completed fellowships in both Pediatric Neuropsychiatry and Child and Adolescent Psychiatry. He is board-certified in both Child & Adolescent Psychiatry and Psychiatry. Dr. Horrigan also holds appointments as Clinical Associate Professor at the University of North Carolina, and Associate Consulting Professor in the Department of Psychiatry and Behavioral Sciences at Duke University School of Medicine. is a member of the board for the International Rett Syndrome Foundation, and science advisory board of the FRAXA research foundation